Chen Ran-Chou, Chen Wei-Tsung, Tu Hsing-Yang, Cheng Nai-Yuan, Wang Chung-Kwe, Liao Li-Ying, Wang Chaur-Shine, Chen Pao-Huei
Department of Radiology, Taipei Municipal Jen-Ai Hospital, 10, Sec. 4, Jen-Ai Rd., 106, Taipei, Taiwan.
AJR Am J Roentgenol. 2002 Jan;178(1):67-73. doi: 10.2214/ajr.178.1.1780067.
The purpose of the study was to compare power Doppler sonography with intraarterial CO(2)-enhanced sonography for revealing vascularity in treated and untreated hepatic tumors.
Fifty-five patients with 93 liver tumors were prospectively examined with power Doppler sonography and CO(2)-enhanced sonography. These tumors included 29 hepatocellular carcinomas in patients with no previous treatment, 26 treated hepatocellular carcinomas, and 38 hemangiomas. The vascular depiction of power Doppler sonography was compared with that obtained in the early phase of CO(2)-enhanced sonography. The results of angiography were also recorded for comparison.
In the hepatocellular carcinomas, power Doppler sonography was the same as CO(2)-enhanced sonography in 18 (62%) of 29 tumors, was inferior to CO(2)-enhanced sonography in nine (31%) of 29 tumors, and was superior to CO(2)-enhanced sonography in two (7%) of 29 tumors. In the treated hepatocellular carcinomas, power Doppler sonography was the same as CO(2)-enhanced sonography in 15 (58%) of 26 tumors and was inferior in 11 (42%) of 26 tumors. In hemangiomas, the same vascularity was found in both studies in 15 (39%) of 38 tumors, CO(2)-enhanced sonography was superior in 22 (58%) of 38 tumors, and power Doppler sonography was superior in one (3%) of 38 tumors. As a whole, 45% of the 93 tumors showed better vascular depiction on CO(2)-enhanced sonography. However, 19.4% of tumors were hypovascular using power Doppler sonography but hypervascular using CO(2)-enhanced sonography.
Power Doppler sonography is a useful technique for screening hepatic tumor vascularity. CO(2)-enhanced sonography is superior to power Doppler sonography in depicting tumor vascularity in treated hepatocellular carcinomas and in hemangiomas, especially small hemangiomas.
本研究旨在比较能量多普勒超声与动脉内二氧化碳增强超声在显示已治疗和未治疗肝肿瘤血管方面的效果。
对55例患有93个肝肿瘤的患者进行前瞻性的能量多普勒超声和二氧化碳增强超声检查。这些肿瘤包括29例未经治疗的肝细胞癌患者、26例已治疗的肝细胞癌患者以及38例肝血管瘤患者。将能量多普勒超声的血管显示情况与二氧化碳增强超声早期获得的结果进行比较。还记录了血管造影的结果以作对比。
在肝细胞癌中，29个肿瘤中有18个（62%）的能量多普勒超声与二氧化碳增强超声相同，29个肿瘤中有9个（31%）能量多普勒超声不如二氧化碳增强超声，29个肿瘤中有2个（7%）能量多普勒超声优于二氧化碳增强超声。在已治疗的肝细胞癌中，26个肿瘤中有15个（58%）的能量多普勒超声与二氧化碳增强超声相同，26个肿瘤中有11个（42%）能量多普勒超声不如二氧化碳增强超声。在肝血管瘤中，38个肿瘤中有15个（39%）在两项研究中显示相同的血管情况，38个肿瘤中有22个（58%）二氧化碳增强超声更优，38个肿瘤中有1个（3%）能量多普勒超声更优。总体而言，93个肿瘤中有45%在二氧化碳增强超声上显示出更好的血管显示。然而，19.4%的肿瘤在能量多普勒超声下为低血管，但在二氧化碳增强超声下为高血管。
能量多普勒超声是筛查肝肿瘤血管的一种有用技术。在显示已治疗的肝细胞癌和肝血管瘤（尤其是小肝血管瘤）的肿瘤血管方面，二氧化碳增强超声优于能量多普勒超声。
